BioSpace News Archive

T-Cure Bioscience, Inc. announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application to initiate a Phase I clinical study evaluating a TCR-based product candidate for the treatment of tumors expressing Kita-Kyushu lung cancer antigen 1, such as gastric, cervical, lung, breast cancers and other KK-LC-1 positive epithelial cancers.

Dental prostheses can be immediately placed on replacement teeth with highly predictable outcomes during jaw reconstruction that involves taking bone from the patient’s leg, a new study finds.

Ethris GmbH announced that its lead COVID-19 therapeutic candidate, ETH47, has been awarded “Most Innovative Product Top 3" in the category of Leap Innovations at the Pharma Trend Image & Innovation Awards 2021.

Mediar Therapeutics announced Simon Sturge has joined the firm as executive chairman.

ChromaDex Corp. (NASDAQ:CDXC) issued the following statement: ChromaDex announced today plans to appeal a September 14 decision granting a Motion for Summary Judgment (MSJ) in its lawsuit for patent infringement against Elysium Health, Inc. (“Elysium”) in the United States District Court for the District of Delaware. ChromaDex licenses U.S. Patent No. 8,383,086

Indaptus Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Company’s platform technology.

Ms. Barnett brings a wealth of financial experience to Immunovant Expands executive leadership team as Immunovant plans to return to the clinic across multiple indications

Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection

U.S. FDA Grants BRUKINSA ® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma

Ivantis to Pay $60 Million and Ongoing Double-Digit Royalty to Glaukos